Overview

Methylene Blue as a Third-line Vasopressor in Septic Shock

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A randomized, prospective study comparing ProvayBlue® to standard care with multiple sympathomimetic vasopressors.
Phase:
Phase 2
Details
Lead Sponsor:
Carilion Clinic
Collaborator:
Provepharm Life Solutions
Treatments:
Benzocaine
Methylene Blue
Oxymetazoline
Phenylephrine
Vasoconstrictor Agents